ライフサイエンスコーパス: esophageal

1 e [GERD]), to document physiologic levels of esophageal acid exposure in the distal esophagus with ab

2 Elevated fasting esophageal acid exposure mediated symptoms.

3 Esophageal adenocarcinoma (EA) and its premalignant lesi

4 ce of head and neck cancer (HNC; n = 2,453), esophageal adenocarcinoma (EA; n = 855), esophageal squa

5 gnostic prediction of the clinical course in esophageal adenocarcinoma (EAC) are still not implemente

6 n and biological role of ITGAV expression in esophageal adenocarcinoma (EAC) has not been analyzed so

7 The poor outcomes in esophageal adenocarcinoma (EAC) prompted us to interroga

8 d survival in patients with locally advanced esophageal adenocarcinoma (EAC) treated with neoadjuvant

9 esophagus (BE) can progress to dysplasia and esophageal adenocarcinoma (EAC), accompanied by mutation

10 patients with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), from 1992 through 2015,

11 sophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC).

12 which Barrett's esophagus (BE) progresses to esophageal adenocarcinoma (EAC).

13 ) predisposes for the malignant condition of esophageal adenocarcinoma (EAC).

14 es (LNR) is an indicator of cancer burden in esophageal adenocarcinoma and may identify patients who

15 ng adjuvant therapy for patients with distal esophageal adenocarcinoma and no pathologic evidence of

16 emometrics to assess the phospholipidomes of esophageal adenocarcinoma and relevant control tissues.

17 ent trimodality therapy for locally advanced esophageal adenocarcinoma between 1995 and 2017.

18 of 117 patients were highly discriminant for esophageal adenocarcinoma both in discovery (AUC = 0.97)

19 tically, silencing the carbon switch ACLY in esophageal adenocarcinoma cells shortened glycerophospho

20 , DESI-MSI can objectively identify invasive esophageal adenocarcinoma from a number of premalignant

21 n the management of subsets of clinical T1N0 esophageal adenocarcinoma is controversial.

22 whether MSI can objectively identify primary esophageal adenocarcinoma is currently unknown and repre

23 The incidence of esophageal adenocarcinoma is rising, survival remains po

24 cleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma.

25 Among many other changes, esophageal adenocarcinoma samples were markedly enriched

26 inical T1aN0 (n = 2545) and T1bN0 (n = 1281) esophageal adenocarcinoma that received either ER (cT1a,

27 s, these methods were applied for a model of esophageal adenocarcinoma that was previously calibrated

28 itive disease in patients with cT1a and cT1b esophageal adenocarcinoma were 4% and 15%, respectively.

29 585 patients with esophageal adenocarcinoma were analyzed immunohistochemi

30 d to identify adult patients with pT2-4aN0M0 esophageal adenocarcinoma who underwent definitive surge

31 upfront, complete resection of node-positive esophageal adenocarcinoma, AC was associated with improv

32 uent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent

33 esected, pathologically node-negative distal esophageal adenocarcinoma, independent of presence of hi

34 ) and those with other main risk factors for esophageal adenocarcinoma, such as older age, male sex,

35 reased risk for Barrett's esophagus (BE) and esophageal adenocarcinoma.

36 k T2-4a, pathologically node-negative distal esophageal adenocarcinoma.

37 sophageal strictures, Barrett esophagus, and esophageal adenocarcinoma.

38 t upfront, complete resection of pT1-4N1-3M0 esophageal adenocarcinoma.

39 patients with completely resected pT2-4aN0M0 esophageal adenocarcinoma.

40 g-term outcomes for clinical T1aN0 and T1bN0 esophageal adenocarcinoma.

41 esophagectomy in node-negative cT1a and cT1b esophageal adenocarcinoma.

42 ing intervals: for baseline diagnosis of HGD/esophageal adenocarcinoma: at 3, 6, and 12 months and an

43 Esophageal adenocarcinomas (EACs) are heterogeneous and

44 Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal gr

45 Barrett's esophagus (BE) is a precursor to esophageal adenocarinoma, and screening for cancer risk

46 cal regulator of cell fate decisions between esophageal and pulmonary morphogenesis, and its lack of

47 We collected esophageal and stomach tissues and performed histology,

48 oma registered in the Population Registry of Esophageal and Stomach Tumours of Ontario (PRESTO) betwe

49 Esophageal atresia (EA/TEF) is a common congenital abnor

50 wing surgical and critical care for long-gap esophageal atresia (LGEA) - in comparison to healthy inf

51 c surgery has become a routine operation for esophageal atresia repair.

52 ted Klippel-Feil syndrome, renal agenesis or esophageal atresia.

53 es of thoracoscopic to thoracotomy repair of esophageal atresia.

54 es comparing thoracoscopy to thoracotomy for esophageal atresia.

55 ANO1 was expressed within the esophageal basal zone, and expression correlated positiv

56 onal heartburn requires upper endoscopy with esophageal biopsies to rule out anatomic and mucosal abn

57 mined mRNA and protein expression of ANO1 in esophageal biopsy samples from patients with EoE and in

58 We observed increased ANO1 expression in esophageal biopsy samples from patients with EoE and in

59 ry esophageal fibroblasts were isolated from esophageal biopsy samples of healthy donors or patients

60 Baseline and week 16 esophageal biopsy samples were taken from 69 patients wh

61 ion to histologic and endoscopic assessment, esophageal biopsy specimens were examined for expression

62 ype 2 immunity-associated gene expression in esophageal biopsy specimens, aiming to determine the deg

63 dle-age man with EoE since 2004, had a total esophageal bolus obstruction while eating lunch at the l

64 ned (10-y HR: 1.05; 95% CI: 1.00, 1.11), and esophageal cancer (10-y HR: 1.14; 95% CI: 1.04, 1.26).

65 1.51, 95% CI 1.23-1.84) but similar risk for esophageal cancer (HR 0.95, 95% CI 0.53-1.70), and ONJ (

66 kerosene was associated with higher risk of esophageal cancer (HR: 1.84; 95% CI: 1.10, 3.10).

67 ure, 8.18 vertebral fracture, 1.14 AFF, 0.21 esophageal cancer and 0.09 ONJ events per 1,000 person-y

68 Active surveillance for patients with esophageal cancer and a clinically complete response (cC

69 f cancer progression, but the innervation of esophageal cancer and its clinicopathologic significance

70 erine, and cervical cancer and lower odds of esophageal cancer and melanoma but not associated with 1

71 r pancreatic, kidney, uterine, cervical, and esophageal cancer and melanoma, respectively.

72 y options for patients with locally advanced esophageal cancer and provide recommended care options f

73 ncer, stomach cancer, pancreatic cancer, and esophageal cancer are leading causes of cancer-related d

74 cic or transhiatal esophagectomy for primary esophageal cancer between 2011-2015 were included.

75 In vitro, NGF production in esophageal cancer cells was shown by Western blot, and e

76 cancer cells was shown by Western blot, and esophageal cancer cells were able to induce neurite outg

77 e study was performed in 4 high-volume Dutch esophageal cancer centers between November 2009 and Apri

78 ients undergoing curative-intent surgery for esophageal cancer from 2011 to 2017 in 3 high-volume cen

79 who underwent transhiatal esophagectomy for esophageal cancer from March 2010 to March 2016.

80 Esophageal cancer in females should be considered a uniq

81 RNA that may explain the higher incidence of esophageal cancer in male smokers.

82 Esophageal cancer is a male predominant disease, and sex

83 achieves DC(50) values of 6.0 and 2.6 nM in esophageal cancer KYSE520 and acute myeloid leukemia MV4

84 ollected data from consecutive patients with esophageal cancer localized in the distal esophagus or g

85 MIE negatively affect long-term survival of esophageal cancer patients.

86 used to identify patients with nonmetastatic esophageal cancer receiving either DCR (n = 5977) or neo

87 Some 616 patients undergoing open esophageal cancer surgery between April 2, 2001 and Dece

88 ohort study enrolled 616 patients undergoing esophageal cancer surgery during 2001 to 2005, with 10 y

89 Esophageal cancer surgery is an exemplar of major operat

90 Pneumonia is commonly documented following esophageal cancer surgery, and reducing its incidence is

91 ients from 20 European Centers who underwent esophageal cancer surgery, and were disease-free at leas

92 AKI is common but mostly self-limiting after esophageal cancer surgery.

93 iderably impaired HRQOL up to 10 years after esophageal cancer surgery.

94 The palmoplantar keratinization and esophageal cancer syndrome, tylosis with esophageal canc

95 c dilatation in patients with lower thoracic esophageal cancer undergoing transhiatal esophagectomy.

96 omy (MIE) versus open esophagectomy (OE) for esophageal cancer using a nationwide propensity-score ma

97 PFS for patients with esophageal cancer was associated with MTV and with IMH.K

98 However, 15% of patients with cT1b esophageal cancer were found to have positive nodal dise

99 ve review of 1958 patients (21% female) with esophageal cancer who underwent esophagectomy at a singl

100 The risks of GI cancers combined, esophageal cancer, and gastric cancer were lower when bi

101 ients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes and fi

102 Tumor entities comprised esophageal cancer, colon cancer, rectal cancer and pancr

103 and esophageal cancer syndrome, tylosis with esophageal cancer, is linked to mutations in RHBDF2 enco

104 2 high volume centers for the management of esophageal cancer.

105 nd surgery in patients with locally advanced esophageal cancer.

106 n technique as a treatment for patients with esophageal cancer.

107 ratify after chemoradiotherapy for localized esophageal cancer.

108 ter neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer.

109 eatment regime in patients with locoregional esophageal cancer.

110 component of the management of patients with esophageal cancer.

111 or detecting residual disease after nCRT for esophageal cancer.

112 (perineural invasion) was detected in 12% of esophageal cancers and was associated with reduced survi

113 Nerves were detected in 38% of esophageal cancers and were more associated with squamou

114 ata suggest that innervation is a feature in esophageal cancers that may be driven by cancer cell-rel

115 d in healthy volunteers and in patients with esophageal cancers.

116 ority MOMP." We asked whether reflux-induced esophageal carcinogenesis occurred via minority MOMP and

117 aturated phosphatidylglycerols contribute to esophageal carcinogenesis.

118 actor for the most important risk factor for esophageal carcinoma (ie, BE).

119 hat could be used for hospital comparison in esophageal carcinoma care.

120 y therapy for patients with locally advanced esophageal carcinoma is recommended.

121 cer Audit who underwent potentially curative esophageal carcinoma surgery in 2011 to 2018, were inclu

122 reasingly used in treatment of patients with esophageal carcinoma.

123 Patients monitored by an esophageal catheter and a 32-electrode electrical impeda

124 ed children who had a contraindication to an esophageal catheter or respiratory inductance plethysmog

125 We analyzed publicly available esophageal CD3(+) T-cell single-cell sequencing data for

126 data identify a functional role for ANO1 in esophageal cell proliferation and BZH in patients with E

127 Transcriptional responses of human esophageal cells to IL-13 and the PPIs omeprazole and es

128 hasic PFA induced no chronic histopathologic esophageal changes, while RFA demonstrated a spectrum of

129 1 of whom were later diagnosed with stomach, esophageal, colorectal, lung or liver cancer within four

130 ablation should be applied to 1) all visible esophageal columnar mucosa; 2) 5-10 mm proximal to the s

131 ed to dysphagia, occurring immediately after esophageal contact with specific foods.

132 ucibly in 40% of surveyed EoE patients after esophageal contact with specific foods.

133 om within the inferior vena cava at areas of esophageal contact.

134 t the risk of PV stenosis, artery, nerve, or esophageal damage.

135 for atrial fibrillation ablation to prevent esophageal damage.

136 ected toward the inferior vena cava using an esophageal deviation balloon, and ablation was performed

137 Although esophageal dilation appears to be relatively safe, there

138 ologic features and symptom resolution after esophageal dilation despite histologic features of activ

139 ssed from elemental formula for children and esophageal dilation for adults to selective exclusion of

140 Esophageal dilation might be required to increase lumina

141 in the esophageal microbiome correlate with esophageal disease, but the effects of proton pump inhib

142 Dupilumab increased esophageal distensibility and was generally well tolerat

143 Dupilumab increased esophageal distensibility by 18% vs placebo (P < .0001).

144 lized features (endoscopic reference score), esophageal distensibility, and safety.

145 od antigen-mediated disease characterized by esophageal dysfunction and intraepithelial eosinophil ac

146 Symptoms reflect esophageal dysfunction, and typical endoscopic features

147 eosinophils, as reported by CD41, predicted esophageal eosinophil count.

148 ical glucocorticosteroids effectively reduce esophageal eosinophil counts to <15 per high-power field

149 tary strategies may be effective in reducing esophageal eosinophil counts to <15 per high-power field

150 y safe, there is no evidence that it reduces esophageal eosinophil counts.

151 EoE (2 episodes of dysphagia/week with peak esophageal eosinophil density of 15 or more eosinophils

152 ophilic esophagitis (EoE) and extremely high esophageal eosinophilia have a distinct endotype defined

153 to specific food antigens, leading to dense esophageal eosinophilia, chronic inflammation, and esoph

154 t of proton pump inhibitors in patients with esophageal eosinophilia.

155 ed in disease-relevant cell types, including esophageal epithelia, fibroblasts, and immune cells, wit

156 yses and ion transport assays on an in vitro esophageal epithelial 3-dimensional model system (EPC2-A

157 Using an in vitro esophageal epithelial 3-dimensional model system reveale

158 Human esophageal epithelial cells robustly responded to PPI st

159 the IL-13-induced proliferative response of esophageal epithelial cells.

160 between expression and function of ANO1 and esophageal epithelial proliferation in patients with EoE

161 of ANO1-dependent Cl(-) transport abrogated esophageal epithelial proliferation.

162 ized that PPIs can counteract IL-13-mediated esophageal epithelial responses that are germane for EoE

163 The mechanisms underlying esophageal epithelial responses to PPIs remain poorly un

164 dle age, normal human tissues, including the esophageal epithelium (EE), become a patchwork of mutant

165 induced Cl(-) transport mechanism within the esophageal epithelium, and that loss of ANO1-dependent C

166 results demonstrate broad effects of PPIs on esophageal epithelium, including their ability to curtai

167 and Trp53, which are also selected in human esophageal epithelium.

168 Eosinophils tethered to esophageal fibroblasts after LIGHT stimulation via inter

169 LIGHT mediates interactions between esophageal fibroblasts and eosinophils via ICAM1.

170 Human primary esophageal fibroblasts were isolated from esophageal bio

171 Stimulation of esophageal fibroblasts with LIGHT induced inflammatory g

172 geal eosinophilia, chronic inflammation, and esophageal fibrosis.

173 tion features, compared with normal tissues (esophageal, gastric, and duodenum; controls) from the sa

174 165) and five types of pain and discomfort (esophageal, gastric, and rectal distension, cutaneous th

175 essed in gastrointestinal cancers, including esophageal, gastric, colorectal, and pancreatic cancers.

176 We show that parasites lacking the esophageal gland are unable to lyse ingested immune cell

177 Intriguingly, schistosomes lacking the esophageal gland die after transplantation into naive mi

178 role, we examine schistosomes that lack the esophageal gland due to knockdown of a forkhead-box tran

179 and root-knot nematodes revealed a subset of esophageal gland related sequences and putative effector

180 LF3) from M. incognita were expressed in the esophageal gland with high expression during the parasit

181 an immune-evasion mechanism mediated by the esophageal gland, which is essential for schistosome sur

182 ch blocks development and maintenance of the esophageal gland, without affecting the development of o

183 biomass was associated with higher risks of esophageal [hazard ratio (HR): 1.89; 95% confidence inte

184 mized study was conducted to compare risk of esophageal heating and acute procedure success of differ

185 Esophageal heating during ablation is the result of a ti

186 Then, we used 1704 unique esophageal high-resolution images of rigorously confirme

187 rule out anatomic and mucosal abnormalities, esophageal high-resolution manometry to rule out major m

188 udy, we aimed to investigate risk factors of esophageal injury (EI) caused by catheter ablation for A

189 In an in vivo porcine esophageal injury model, we compared the effects of newe

190 In contrast, esophageal injury occurred in all RFA animals (4 of 4, 1

191 In contrast, no lung, vagal nerve, or esophageal injury was observed at PFA sites.

192 In this novel porcine model of esophageal injury, biphasic PFA induced no chronic histo

193 -14] mm) produced transmural lesions without esophageal injury.

194 ded infusion of VacA did not damage stomach, esophageal, intestinal, or liver tissue.

195 so assessed histologic features of EoE (peak esophageal intraepithelial eosinophil count and EoE hist

196 At week 12, dupilumab reduced the peak esophageal intraepithelial eosinophil count by a mean 86

197 Esophageal intramural pseudodiverticulosis is an uncommo

198 Esophageal intramural pseudodiverticulosis is associated

199 agram and esophagogastroduodenoscopy to have esophageal intramural pseudodiverticulosis, complicated

200 treatment of an uncommon cause of dysphagia, esophageal intramural pseudodiverticulosis.

201 ntubation-associated events (cardiac arrest, esophageal intubation with delayed recognition, emesis w

202 Using human esophageal keratinocytes, we have identified Twist2 as a

203 any cancer sites, but decreased for stomach, esophageal, laryngeal, Hodgkin lymphoma, and testicular

204 hanges, while RFA demonstrated a spectrum of esophageal lesions including fistula and deep esophageal

205 sy, no PFA animals (0 of 6, 0%) demonstrated esophageal lesions.

206 6.5 [15-18] applications) applied inside the esophageal lumen produced mild edema compared with RFA (

207 tiple small outpouchings protruding from the esophageal lumen.

208 65 to 99 who underwent surgery for pancreas, esophageal, lung, rectal, and colon cancer from 2014 to

209 Medicare patients underwent either pancreas, esophageal, lung, rectal, or colon resection for cancer

210 ericardial fistula is a rare complication of esophageal malignancy, trauma, or surgery.

211 t or if the diagnosis is unclear, endoscopy, esophageal manometry, and esophageal pH monitoring are r

212 expression of newly-identified tracheal and esophageal markers in Sox2/Nkx2-1 compound mutants.

213 on pump inhibitor omeprazole can reduce both esophageal mast cell and eosinophil numbers and attenuat

214 m to cause significant changes in the distal esophageal microbial community.

215 Changes in the esophageal microbiome correlate with esophageal disease,

216 l esophagus were analyzed using a customized esophageal microbiome qPCR panel array (EMB).

217 oE), an allergic inflammatory disease of the esophageal mucosa.

218 No eosinophils were found in the esophageal mucosa.

219 Significant ablation-related esophageal necrosis, inflammation, and fibrosis were see

220 stinal lymphadenectomy included the low para-esophageal nodes (n=815, 95%), subcarinal nodes (n = 774

221 f complications, and factors associated with esophageal or gastric lesions following TEE manipulation

222 al lesions and showed lower vulnerability to esophageal or phrenic nerve damage compared with RFA.

223 stance and surgical volume on outcomes after esophageal, pancreatic, and rectal cancer resections.

224 Database (2004-2016), patients who underwent esophageal, pancreatic, or rectal resections at far HVH

225 nclear, endoscopy, esophageal manometry, and esophageal pH monitoring are recommended.

226 colized nuclear scintigraphy (n=83), 24-hour esophageal pH monitoring, and stationary manometry (n=14

227 Future studies with larger sample sizes and esophageal pH testing should be performed to determine t

228 Clinical features, tidal change in esophageal pressure (DeltaPes), tidal change in dynamic

229 Inspiratory effort was estimated by esophageal pressure (Pes) swings.

230 demonstrated acute elevations of the gastro-esophageal pressure gradient (>10mmHg) underpinned most

231 requent, significant elevation in the gastro-esophageal pressure gradient was the mechanism of reflux

232 ted well with measures of drive and with the esophageal pressure-time product (within-subjects R(2) =

233 ing derivation and validation datasets using esophageal pressure-time product as the reference standa

234 vated chloride channel anoctamin 1 (ANO1) in esophageal proliferation and the histopathologic feature

235 rve following the progressive opening of the esophageal prosthesis.

236 No esophageal protection strategy was used.

237 gical strategy but deserve discussion before esophageal reconstruction for caustic injuries.

238 resection and in 99 (74%) patients underwent esophageal reconstruction.

239 Antireflux surgery for gastro-esophageal reflux disease is followed by varying rates o

240 rative complications or recurrence of gastro-esophageal reflux disease.

241 eflux only and 4 patients were found to have esophageal remnants in addition to reflux.

242 tions, including cardiac, vertebral, tracheo-esophageal, renal and limb defects.

243 Emergency esophageal resection was significantly associated with h

244 ents undergoing transthoracic or transhiatal esophageal resections.

245 o pathologic tissue remodeling, with ensuing esophageal rigidity and loss of luminal diameter caused

246 Four discrete esophageal sites were targeted in each animal: 6 animals

247 Smooth muscles of the lower esophageal sphincter (LES) and skeletal muscle of the cr

248 The lower esophageal sphincter and crural diaphragm constitute the

249 (pH parameters, endoscopic signs, and lower esophageal sphincter pressure changes).

250 e, we obtain a detailed immune cell atlas of esophageal squamous cell carcinoma (ESCC) at single-cell

251 stric atrophy as a potential risk factor for esophageal squamous cell carcinoma (ESCC) have been inco

252 Esophageal squamous cell carcinoma (ESCC) is among the m

253 Detection of patients with esophageal squamous cell carcinoma (ESCC) who do not ben

254 MicroRNA-31 (miR-31) is overexpressed in esophageal squamous cell carcinoma (ESCC), a deadly dise

255 pe and characterize the oncogenic drivers of esophageal squamous cell carcinoma (ESCC).

256 tive tract is linked to an increased risk of esophageal squamous cell carcinoma (ESCC).

257 ant role in the etiology and pathogenesis of esophageal squamous cell carcinoma (ESCC).

258 3), esophageal adenocarcinoma (EA; n = 855), esophageal squamous cell carcinoma (n = 267), and gastri

259 melanoma, multiple myeloma, oral cancer, and esophageal squamous cell carcinoma did not survive corre

260 from 100 patients with HGD or EAC and normal esophageal squamous mucosa (controls).

261 CC might differ from other solid tumors like esophageal squamous-cell carcinoma or glioma.

262 A CT scan detected the injury and a covered esophageal stent was inserted within 2 h from the injury

263 ssigned 1:1 to esophageal stimulation via an esophageal stimulating catheter (E-Motion Tube; E-Motion

264 Esophageal stimulation via a special feeding catheter di

265 Patients were randomly assigned 1:1 to esophageal stimulation via an esophageal stimulating cat

266 mune activity was increased in EP300 mutated esophageal, stomach and prostate cancers.

267 senting symptom is dysphagia with associated esophageal stricture formation.

268 Esophageal strictures more commonly occurred in L-EoE (P

269 iated with an increased risk of esophagitis, esophageal strictures, Barrett esophagus, and esophageal

270 t years behaviorally compensating for narrow esophageal strictures.

271 Complications after esophageal surgery negatively affect HRQOL, but it is un

272 andardize international outcome reporting in esophageal surgery, the ECCG developed a standardized ou

273 enetriaminepentaacetic acid in water for the esophageal-swallow study and then 300 mL for a 30-min (1

274 global health assessed with EORTC-QLQC30 and esophageal symptoms assessed with EORTC-OES18.

275 th 40 W is associated with a similar rate of esophageal temperature alerts and a lower atrial fibrill

276 Esophageal temperature alerts occurred in a similar prop

277 f the study was the occurrence and number of esophageal temperature alerts per patient during ablatio

278 The necrotic RFA lesions involved multiple esophageal tissue layers with evidence of arteriolar med

279 Esophageal tissues from in pL2.Lgr5.N2IC mice had increa

280 T cells in esophageal tissues from patients with EoE express increa

281 LIGHT was up-regulated in the esophageal tissues from patients with EoE, compared with

282 Esophageal tissues from pL2.Lgr5.p65fl/fl mice had lower

283 Esophageal tissues were obtained from pediatric patients

284 In human esophageal tissues, progression of BE to EAC was associa

285 scover that the majority of the tracheal and esophageal transcriptome is NKX2-1 independent.

286 Images and quantification were obtained for esophageal transit, water-only gastric emptying, water-w

287 er, as well as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophag

288 ication and analysis of ctDNA from localized esophageal tumors.

289 sophageal lesions including fistula and deep esophageal ulcers and abscesses.

290 ding one esophago-pulmonary fistula and deep esophageal ulcers in the other animals.

291 ic encephalopathy, hepatocellular carcinoma, esophageal variceal bleed, and spontaneous bacterial per

292 stemic shunt and for the treatment of gastro-esophageal variceal hemorrhage in patients with decompen

293 n analysis of a subgroup of patients without esophageal varices at baseline (n = 81), 2 mg/kg belapec

294 Portal hypertension and esophageal varices needing treatment could be predicted

295 eeding, encephalopathy, or jaundice) without esophageal varices was included, and 5-year outcome is r

296 , in a subgroup analysis of patients without esophageal varices, 2 mg/kg belapectin did reduce HVPG a

297 s (ECOG PS) 0-1, and following management of esophageal varices, when present, according to instituti

298 PLWH) are at increased risk of cirrhosis and esophageal varices.

299 Abscess formation and full-thickness esophageal wall disruptions were seen in areas of perfor

300 it, led to a total intramural ruptur of the esophageal wall.